The merger is effectively an acquisition of Werewolf by Ambros via reverse merger, with Werewolf stockholders retaining only ~6.4% of the combined entity. The deal is contingent on stockholder approval of required proposals and Nasdaq listing approval. Watch for stockholder vote on proposals and any delays in Nasdaq listing confirmation. If the merger fails, Werewolf faces going-concern risk and potential dissolution.
Price Chart
Executive Summary
Werewolf Therapeutics (HOWL) filed an S-4 registration statement for its merger with Ambros Therapeutics, where Ambros will be the accounting acquirer in a reverse recapitalization. The merger values Ambros at $500M and Werewolf at $47.5M, with a concurrent $150M PIPE financing. Pre-merger Werewolf stockholders will own approximately 6.4% of the combined company, while Ambros holders will own ~72% and PIPE investors ~21.6%. Werewolf stockholders will receive CVRs tied to proceeds from legacy WTX-124/WTX-330 assets. The combined company will trade under AMBX, and the merger is expected to close in Q1 2027.
Key Facts
- Merger values Ambros at $500M equity value and Werewolf at $47.5M equity value
- Concurrent PIPE financing of $150M from investors
- Pre-merger Werewolf holders will own ~6.4% of combined company; Ambros holders ~72%; PIPE investors ~21.6%
- Werewolf stockholders to receive one CVR per share for legacy WTX-124/WTX-330 programs
- Combined company to trade on Nasdaq under symbol AMBX
- Werewolf has substantial doubt about its ability to continue as a going concern
- Werewolf had $22M cash as of June 30, 2026, with $485.3M accumulated deficit
- Ambros lead candidate neridronate is in Phase 3 for CRPS-1; prior Phase 3 trials by Grnenthal were terminated early
- Ambros had $103.2M cash as of June 30, 2026, with $60.8M accumulated deficit
- Termination fee of $1.9M payable by Werewolf to Ambros if deal fails under certain conditions
Financial Impact
Werewolf pre-merger equity holders diluted to ~6.4% of combined company; $150M PIPE at $47.5M Werewolf valuation vs $500M Ambros valuation; Werewolf had $22M cash vs $485.3M accumulated deficit
Risk Factors
- Risk of merger failure: Werewolf's ability to continue as a going concern; termination fee of $1.9M payable by Werewolf if deal fails
- Dilution risk: Werewolf holders own only ~6.4% post-merger; Ambros holders own ~72%
- Regulatory risk: Ambros' neridronate Phase 3 trial failed Phase 3 trials; FDA may require additional trials needed
- Nasdaq listing risk: Combined company must obtain listing approval; no assurance listing condition will be met
Investment Themes
Documents Analyzed
This report is based on 2 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-4 Filing (Primary) | 0001140361-26-037334 |
| Document: ny20081588x1_ex10-40.htm | 0001140361-26-037334 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | S-4/A | — | awaiting T+5 | — | — |
Sep 22, 2026 4w ago | S-4 | $0.9894 $0.9223 | ▲ +6.78% | ▲ +6.11% | $0.9800 (+0.95%) |
Sep 21, 2026 5w ago | SC 13G | $0.9800 $0.9300 | ▼ −5.10% | ▼ −4.08% | $0.9800 (+0.00%) |
Aug 21, 2026 9w ago | 425 | $0.8740 $0.9433 | ▲ +7.93% | ▲ +7.46% | $0.9800 (+12.13%) |
Aug 21, 2026 9w ago | 8-K | $0.8740 $0.9433 | ▲ +7.93% | ▲ +7.46% | $0.9800 (+12.13%) |
Aug 21, 2026 9w ago | Press Release | $0.8740 $0.9433 | ▼ −7.93% | ▼ −7.46% | $0.9800 (−12.13%) |
Jul 31, 2026 12w ago | 8-K | $0.3531 $0.3971 | ▲ +12.46% | ▲ +8.95% | $0.9800 (+177.54%) |
Jul 31, 2026 12w ago | Press Release | $0.3531 $0.3971 | ▲ +12.46% | ▲ +8.95% | $0.9800 (+177.54%) |
Jun 29, 2026 17w ago | 144 | $0.3599 $0.3200 | ▲ +11.09% | ▲ +11.69% | $0.9800 (−172.30%) |
Jun 29, 2026 17w ago | 144 | $0.3599 $0.3200 | ▲ +11.09% | ▲ +11.69% | $0.9800 (−172.30%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers